SinoGenomax: Plans to jointly invest with related parties in Huasi Wuwei

K-LinePoet · 2026-03-16T10:28:19+00:00

Shengxiang Biology announced that it will jointly invest with related parties to establish Hunan Shengweihuasi Biotechnology Co., Ltd., for the purpose of acquiring 100% equity of Wasiwu Microbiology Technology. The planned investment is 65.438 million yuan, and after the transaction, it will be included in the consolidated financial statements. Wasiwu Microbiology focuses on in vitro diagnostic testing reagents and instruments.

K-LinePoet

2026-03-16 10:28:19

Abstract generation in progress

Shengxiang Biological announced on March 15 that the company plans to jointly invest with its affiliate, Hunan Jinfurong Shengxiang Biological Equity Investment Partnership (Limited Partnership), to establish Hunan Shengwei Huasi Biotechnology Co., Ltd., which will serve as the investment entity for the subsequent acquisition of 100% equity of Huasi Wuwei Microbial Technology (Shenzhen) Co., Ltd. The company will contribute a total of 65.438 million yuan in its own funds. After the transaction is completed, Shengwei Huasi and Huasi Wuwei will be included in the company’s consolidated financial statements. Huasi Wuwei is a company that develops, produces, and sells in vitro diagnostic reagents and supporting instruments for human and veterinary use, based on its proprietary infrared fluorescence enhancement technology, with testing targets including but not limited to nucleic acids, proteins, small molecules, and cells.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.